GlobeNewswire: BeiGene, LTD. Contains the last 10 of 235 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:46:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/08/06/2074594/0/en/BeiGene-Reports-Second-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=28344BeiGene Reports Second Quarter 2020 Financial Results2020-08-06T20:05:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the second quarter and first half of 2020.]]>https://www.globenewswire.com/news-release/2020/08/05/2073149/0/en/BeiGene-Announces-Data-on-Tislelizumab-and-Pamiparib-to-Be-Presented-at-the-2020-European-Society-for-Medical-Oncology-ESMO-Virtual-Congress.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress2020-08-05T11:00:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, taking place on September 18-22, 2020.]]>https://www.globenewswire.com/news-release/2020/07/27/2067987/0/en/Priority-Review-Granted-to-BeiGene-s-New-Drug-Application-of-Pamiparib-in-Ovarian-Cancer-in-China.html?f=22&fvtc=4&fvtv=28344Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China2020-07-27T13:15:00Z<![CDATA[BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) of pamiparib, BeiGene’s investigational inhibitor of PARP1 and PARP2, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.]]>https://www.globenewswire.com/news-release/2020/07/17/2063910/0/en/BeiGene-Announces-Acceptance-of-a-New-Drug-Application-of-Pamiparib-in-Ovarian-Cancer-in-China.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China2020-07-17T13:00:00Z<![CDATA[BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of BeiGene’s investigational inhibitor of PARP1 and PARP2, pamiparib, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.]]>https://www.globenewswire.com/news-release/2020/07/15/2062909/0/en/BeiGene-Announces-Closing-of-Approximately-2-08-Billion-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering2020-07-15T21:00:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), to certain existing investors.]]>https://www.globenewswire.com/news-release/2020/07/13/2060945/0/en/BeiGene-Announces-Pricing-of-Approximately-2-08-Billion-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering2020-07-13T00:00:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), to certain existing investors.]]>https://www.globenewswire.com/news-release/2020/07/02/2056819/0/en/BeiGene-to-Host-Investor-Conference-Call-and-Webcast-to-Discuss-the-Company-s-Early-Development-Pipeline-and-Research.html?f=22&fvtc=4&fvtv=28344BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research2020-07-02T11:00:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, July 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will host an investor conference call and webcast on Thursday, July 9, 2020 at 9:00 a.m. ET to discuss the Company’s early development pipeline and research.]]>https://www.globenewswire.com/news-release/2020/07/01/2056574/0/en/BeiGene-Announces-Acceptance-of-a-Supplemental-New-Drug-Application-for-Tislelizumab-in-Patients-with-Previously-Treated-Unresectable-Hepatocellular-Carcinoma-in-China.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China2020-07-01T22:00:00Z<![CDATA[BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.]]>https://www.globenewswire.com/news-release/2020/07/01/2056119/0/en/BeiGene-Announces-Appointment-of-Angus-Grant-as-Chief-Business-Executive.html?f=22&fvtc=4&fvtv=28344BeiGene Announces Appointment of Angus Grant as Chief Business Executive2020-07-01T11:00:00Z<![CDATA[CAMBRIDGE, Mass. and BEIJING, China, July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Angus Grant, Ph.D., as Chief Business Executive. In this role, Dr. Grant will oversee business development, alliance management, and help drive external innovation and investment to guide BeiGene’s global growth strategy. Dr. Grant will report to John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.]]>Angus Grant, Ph.D., Chief Business Executive at BeiGeneAngus Grant, Ph.D., Chief Business Executive at BeiGenehttps://www.globenewswire.com/news-release/2020/06/30/2055916/0/en/BeiGene-Begins-Commercializing-XGEVA-Denosumab-in-China.html?f=22&fvtc=4&fvtv=28344BeiGene Begins Commercializing XGEVA® (Denosumab) in China2020-06-30T23:30:00Z<![CDATA[BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has begun commercializing XGEVA® (denosumab) in China for the treatment of giant cell tumor of bone (GCTB). This marks the first Amgen product that has been transitioned to BeiGene for commercialization in China since the commencement of the parties’ global strategic oncology collaboration in January 2020. Amgen gained approval from the China National Medical Products Administration (NMPA) for XGEVA in May 2019 for the treatment of adults and skeletally mature adolescents (defined by at least one mature long bone and with a body weight ≥ 45 kg) with GCTB that is unresectable or where surgical resection is likely to result in severe morbidity. In addition, a supplemental new drug application (sNDA) for XGEVA as a prevention for skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors has been accepted by the Center for Drug Evaluation (CDE) of the NMPA in April 2020 and is currently under review.]]>